CSAG2, also known as taxol (paclitaxel)-resistance-associated gene-3 (TRAG-3), is overexpressed in paclitaxel-resistant ovarian cancer cells (Duan et al., 1999), and also shown to be negatively associated with clinical outcome after paclitaxel treatment (Lage and Denkert, 2007; Materna et al., 2007). The gene discussed is CSAG2; the disease is ovarian carcinoma.